Up to 200 percent: Trump announces tariffs on drugs

US President Donald Trump has announced plans to impose tariffs on generic medicines, with rates potentially reaching up to 200 percent. The measure, which he outlined on his platform Truth Social, aims to encourage pharmaceutical companies to relocate production within the United States. According to the announcement, initial tariffs of 100 percent would apply starting in the summer of 2028, followed by an increase to 200 percent. These tariffs target imported generic drugs, which are typically cheaper alternatives to patented medications. The proposed policy comes amid growing pressure on the pharmaceutical industry outside the U.S. Trump claimed the move is intended to protect American consumers by reducing high drug prices. He accused pharmaceutical firms of undermining domestic competition through lower-cost production abroad. Additionally, he cited the substantial research costs associated with developing new medications as justification for the tariffs. Under the plan, generic medicine imports into the U.S. would initially face a 100 percent tariff rate beginning in the summer of 2028. This rate would remain in place for one year before increasing to 200 percent. However, Trump stated that until the summer of 2028, no tariffs would be applied to generic medicines. Companies would have this period to shift their manufacturing operations to the United States. Those who fail to comply could face penalties. The president did not specify how the tariffs would be implemented or the legal basis for imposing them. He emphasized that the measures were meant to safeguard the American population. The policy is part of broader efforts to reshape trade practices and reduce reliance on foreign suppliers, particularly in sectors deemed critical to national interests. Earlier this year, Trump had already introduced tariffs of 100 percent on certain branded medications, with phased implementation. Exceptions exist for companies producing goods domestically or under specific trade agreements. The current proposal extends similar logic to generic medicines, aiming to create a more level playing field for U.S.-based manufacturers. In addition to the pharmaceutical sector, Trump recently imposed new tariffs of 25 percent on products from Brazil. These tariffs took effect midweek and apply to a wide range of imports, including agricultural and industrial goods. The decision followed a one-year investigation by the U.S. government, which identified alleged unfair or discriminatory trade practices in Brazil. Exempted items include beef, coffee, orange juice, oil, gas, and certain aircraft components, which either lack sufficient domestic supply or involve sensitive supply chains. These developments reflect ongoing tensions in global trade relations, with the U.S. increasingly using economic tools to influence international markets. While the impact on consumer prices and healthcare access remains unclear, the policies underscore a continued focus on reshaping trade dynamics to favor domestic industries. As the implementation dates approach, further details on enforcement mechanisms and potential exemptions are likely to emerge.